2015 Big Pharma Outlook - What are the significant

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
2015 Big Pharma Outlook - What are the significant challenges and drivers facing Big Pharma out to 2024?

Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/wv...big_pharma ) has announced the addition of the "2015 Big Pharma Outlook" report to their offering. Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies' sharpened focus on highperforming markets. This report explores and visualizes market dynamics in the Big Pharma peer set out to 2024, using in-house sales forecasts. By delving deeper into drivers of strategy, revenue trends, and therapy area focus, this analysis is vital to understanding how the industry will navigate headwinds in order to steer towards robust growth. What's included in this report: - Analyst Outlook - Revenue Analysis - Therapy Area Analysis - Lifecycle Analysis - Strategy Analysis Key questions answered: - What are the significant challenges and drivers facing Big Pharma out to 2024? - Which companies will propel revenue growth over the forecasts period? - Which companies will have leading market share gains and market share losses? - How are late stage pipelines positioned, and what are the most-coveted launch products? - Which therapy areas will experience the largest growth and decline? - What are the portfolio weightings of Big Pharma based on the lifecycle of products? - How is Big Pharma adopting lifecycle management strategies to increase value? Key Topics Covered: 1. About This Report - Analysis structure - Key questions answered - Highlights 2. Analyst Outlook 3. Revenue Analysis - Global revenue overview - Company revenue overview - Top 30 products in 2024 - Big Pharma pipeline overview - Top 30 pipeline products - Company launch portfolios - Five-year launch analysis - Expiry revenue overview - Bibliography 4. Therapy Area Analysis - Worldwide overview - Therapy area ranking - Oncology - Endocrine, metabolic, and genetic disorders - Central nervous system - Bibliography 5. Lifecycle Analysis - Lifecycle management case studies - Biosimilars - Bibliography 6. Strategy Analysis - How has Big Pharma adapted strategically to internal and external headwinds? - Targeted deal-making - Cost-cutting programs - Big Pharma emerging market presence - Bibliography 7. Appendix For more information visit http://www.researchandmarkets.com/research/wv...big_pharma

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI and Storytelling Make Waves in Science Education

Updated Category News Views 4

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 5

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 4

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 4

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 2

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 3

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading

Top 5 Most Recently Viewed Articles

Ten Four Truck Insurance Welcomes Chris Johnstone on Board

Updated Category News Views 76

Exciting Leadership Move at Ten Four Truck Insurance Ten Four Truck Insurance, recognized as a premier provider of insurance solutions tailored specifically for the trucking industry, has recently elevated Chris Johnstone to the position of Director of Partnerships. This strategic appointment is set to enhance the company's collaborative efforts and broaden its partner...

Continue Reading
Innovative Screed Hook Design Enhances Concrete Pouring Process

Updated Category News Views 165

Revolutionizing the Concrete Construction Process In the bustling world of construction, efficiency is key. An inventive mind has recently introduced a specialized screed hook that promises to streamline the concrete pouring process significantly. This innovation is designed with a focus on ease of use, making it a practical addition for contractors and workers alike....

Continue Reading
SCR Expands Offerings Through Global Partnerships in Business Formation

Updated Category News Views 201

SCR Expands Offerings Through Global Partnerships In recent developments, SCR has made significant strides in enhancing its Offshore Company Formation services by forging international partnerships. These collaborations provide businesses and individuals with increased flexibility in establishing structures that can facilitate asset protection, succession planning, and...

Continue Reading
Response Pharmaceuticals Achieves Milestone in RDX-002 Study

Updated Category News Views 171

Response Pharmaceuticals Makes Significant Progress in Clinical Trial Response Pharmaceuticals, Inc., a company specializing in innovative weight management solutions, has announced a pivotal moment in its clinical trajectory. The firm has completed early enrollment in a Phase 2 clinical trial assessing the efficacy of its investigational drug candidate, RDX-002. This...

Continue Reading
Fifth Third Bancorp Faces Decline in Profit Due to Higher Provisions

Updated Category News Views 81

Fifth Third Bancorp Reports Lower Profits Amid Rising Provisions Fifth Third Bancorp (NASDAQ: FITB), a prominent financial institution, has reported a decrease in its profits for the third quarter, primarily influenced by heightened provisions for loan losses. The bank's recent financial disclosures have caught the attention of investors, culminating in a nearly 3% drop...

Continue Reading